- Home
- TIRX vs NXTC Comparison
TIRX vs NXTC Comparison
Compare TIRX & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIRX
- NXTC
- Stock Information
- Founded
- TIRX 2010
- NXTC 2015
- Country
- TIRX China
- NXTC United States
- Employees
- TIRX N/A
- NXTC N/A
- Industry
- TIRX Specialty Insurers
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- TIRX Finance
- NXTC Health Care
- Exchange
- TIRX Nasdaq
- NXTC Nasdaq
- Market Cap
- TIRX 12.0M
- NXTC 13.9M
- IPO Year
- TIRX 2021
- NXTC 2019
- Fundamental
- Price
- TIRX $1.20
- NXTC $0.40
- Analyst Decision
- TIRX
- NXTC Strong Buy
- Analyst Count
- TIRX 0
- NXTC 2
- Target Price
- TIRX N/A
- NXTC $3.50
- AVG Volume (30 Days)
- TIRX 69.4K
- NXTC 340.4K
- Earning Date
- TIRX 08-15-2025
- NXTC 07-31-2025
- Dividend Yield
- TIRX N/A
- NXTC N/A
- EPS Growth
- TIRX N/A
- NXTC N/A
- EPS
- TIRX N/A
- NXTC N/A
- Revenue
- TIRX $3,219,336.00
- NXTC N/A
- Revenue This Year
- TIRX N/A
- NXTC N/A
- Revenue Next Year
- TIRX N/A
- NXTC N/A
- P/E Ratio
- TIRX N/A
- NXTC N/A
- Revenue Growth
- TIRX 158.74
- NXTC N/A
- 52 Week Low
- TIRX $1.07
- NXTC $0.22
- 52 Week High
- TIRX $4.15
- NXTC $1.82
- Technical
- Relative Strength Index (RSI)
- TIRX 42.86
- NXTC 37.68
- Support Level
- TIRX $1.15
- NXTC $0.42
- Resistance Level
- TIRX $1.29
- NXTC $0.50
- Average True Range (ATR)
- TIRX 0.07
- NXTC 0.04
- MACD
- TIRX 0.00
- NXTC -0.01
- Stochastic Oscillator
- TIRX 20.31
- NXTC 4.17
About TIRX TIAN RUIXIANG Holdings Ltd
Tian Ruixiang Holdings Ltd is an Insurance Brokerage firm. It distributes a wide range of insurance products, which are categorized into two groups; property and casualty insurance, such as commercial property insurance, liability insurance, accidental insurance, and automobile insurance; and other insurances, such as health insurance, life insurance, and miscellaneous insurances. It also generates a small amount of revenue from risk management services. The firm act on behalf of its customers seeking insurance coverage from insurance companies. It generates revenue from the provision of insurance brokerage services.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.